BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karampitsakos T, Vraka A, Bouros D, Liossis SN, Tzouvelekis A. Biologic Treatments in Interstitial Lung Diseases. Front Med (Lausanne) 2019;6:41. [PMID: 30931306 DOI: 10.3389/fmed.2019.00041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu L, Wang F, Luo F. Rituximab for the treatment of connective tissue disease–associated interstitial lung disease: A systematic review and meta-analysis. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1019915] [Reference Citation Analysis]
2 Kirgou P, Sinis SI, Dimeas IE, Papanikolaou IC, Tatsis K, Gogali A, Gourgoulianis KI, Bogdanos DP, Daniil Z. Clinical relevance of circulating autoantibodies in idiopathic pulmonary fibrosis; A NAt hard to break. Front Med 2022;9. [DOI: 10.3389/fmed.2022.964722] [Reference Citation Analysis]
3 Liossis SC, Bounia CA. Treating Autoimmune-Related Interstitial Lung Disease With B Cell Depletion. Front Med 2022;9:937561. [DOI: 10.3389/fmed.2022.937561] [Reference Citation Analysis]
4 Hufnagel S, Xu H, Sahakijpijarn S, Moon C, Chow LQ, Williams Iii RO, Cui Z. Dry Powders for Inhalation Containing Monoclonal Antibodies Made by Thin-Film Freeze-Drying. International Journal of Pharmaceutics 2022. [DOI: 10.1016/j.ijpharm.2022.121637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Karampitsakos T, Malakounidou E, Papaioannou O, Dimakopoulou V, Zarkadi E, Katsaras M, Tsiri P, Tsirikos G, Georgiopoulou V, Oikonomou I, Davoulos C, Velissaris D, Sampsonas F, Marangos M, Akinosoglou K, Tzouvelekis A. Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study. Respir Res 2021;22:317. [PMID: 34937570 DOI: 10.1186/s12931-021-01914-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
6 Hufnagel S, Xu H, Sahakijpijarn S, Moon C, Chow LQ, Williams RO, Cui Z. Dry Powders for Inhalation Containing Monoclonal Antibodies Made by Thin-Film Freeze-Drying.. [DOI: 10.1101/2021.10.29.466456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Karampitsakos T, Papaioannou O, Sampsonas F, Tzouvelekis A. Infliximab-induced interstitial lung disease. BMJ Case Rep 2021;14:e245726. [PMID: 34645638 DOI: 10.1136/bcr-2021-245726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kelly CA, Nisar M, Arthanari S, Carty S, Woodhead FA, Price-Forbes A, Middleton D, Dempsey O, Miller D, Basu N, Dawson J, Sathi N, Ahmad Y, Palmer E, Iqbal K, Janakiraman G, Koduri G, Young A. Rheumatoid arthritis related interstitial lung disease - improving outcomes over 25 years: a large multicentre UK study. Rheumatology (Oxford) 2021;60:1882-90. [PMID: 33150434 DOI: 10.1093/rheumatology/keaa577] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 21.0] [Reference Citation Analysis]
9 Vietri L, Cameli P, Perruzza M, Cekorja B, Bergantini L, d'Alessandro M, Refini RM, Pieroni M, Fossi A, Bennett D, Spalletti M, Mazzei MA, Sestini P, Rottoli P, Bargagli E. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena. Ther Adv Respir Dis 2020;14:1753466620906326. [PMID: 32066332 DOI: 10.1177/1753466620906326] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
10 Mikkelsen LF, Rubak S. Reversible lung fibrosis in a 6-year-old girl after long term nitrofurantoin treatment. BMC Pulm Med 2020;20:313. [PMID: 33243181 DOI: 10.1186/s12890-020-01353-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
11 Moll SA, Platenburg MGJP, Platteel ACM, Vorselaars ADM, Janssen Bonàs M, Roodenburg-Benschop C, Meek B, van Moorsel CHM, Grutters JC. Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease. J Clin Med 2020;9:E2944. [PMID: 32933078 DOI: 10.3390/jcm9092944] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Tzouvelekis A, Karampitsakos T, Krompa A, Markozannes E, Bouros D. False Positive COVID-19 Antibody Test in a Case of Granulomatosis With Polyangiitis. Front Med (Lausanne) 2020;7:399. [PMID: 32733908 DOI: 10.3389/fmed.2020.00399] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
13 Shukla SD, Swaroop Vanka K, Chavelier A, Shastri MD, Tambuwala MM, Bakshi HA, Pabreja K, Mahmood MQ, O’toole RF. Chronic respiratory diseases: An introduction and need for novel drug delivery approaches. Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems 2020. [DOI: 10.1016/b978-0-12-820658-4.00001-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Bendstrup E, Vasakova M. Pulmonary invovlement in immunodeficiency. Pulmonary Manifestations of Systemic Diseases 2019. [DOI: 10.1183/2312508x.10015619] [Reference Citation Analysis]
15 Tzouvelekis A, Karampitsakos T, Bouros E, Tzilas V, Liossis S, Bouros D. Autoimmune Biomarkers, Antibodies, and Immunologic Evaluation of the Patient with Fibrotic Lung Disease. Clinics in Chest Medicine 2019;40:679-91. [DOI: 10.1016/j.ccm.2019.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hughes MJ, Sapey E, Stockley R. Neutrophil phenotypes in chronic lung disease. Expert Rev Respir Med 2019;13:951-67. [PMID: 31394045 DOI: 10.1080/17476348.2019.1654377] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]